Nailing of a Doctoral Thesis
"Promoting healing of skin and mucosa by immunomodulation using CXCL12 producing lactic acid bacteria: From bench to bedside" by Industrial PhD student Emelie Öhnstedt.
News
Ilya Pharma is participating in the Jefferies Healthcare Conference in London, Nov 14-16
Interested in learning more about Ilyas's ILP-technology, local-acting immunotherapies or any of the trials SITU-SAFE, SITU-SURGERY, SITU-HEAL or SITU-GUT or our recent work in AMR and meet our CEO Evelina Vågesjö, please reach out.
Nailing of a Thesis - "Live Biotherapeutics - Importance of formulation and lyophilization parameters and an example of a clinical application"
The thesis will be defended in a hearing open to the public at the Swedish University of Agricultural Sciences on Tuesday 5th September (09:00-12:00) in Undervisningshuset Sal L, SLU, Uppsala.
Dr Andreas Fasth will present the planned SITU-SURGERY trial at the US Military partnering conference MHSRS in Kissimmee, FL on August 16
For the third consecutive year Ilya Pharma is invited to share updates regarding its ILP100-Topical program to the US Military largest medical conference, Military Health Systems Research Symposium (MHSRS).
Presentation of science and an update on the ILP100-development at Broad Institute by MIT and Harvard by Professor Mia Phillipson, May 19th in Boston
This week Professor Mia Phillipson is giving a presentation at the Broad Institute of MIT and Harvard in Boston about her research at Uppsala University in gut barrier, immune cell functions and how they can be targeted at the the Peyers Patches and giving an update on Ilya Pharmas ILP100-Oral program for patients experiencing ICI-induced colitis.
Presentation of results from the SITU-SAFE study at EWMA 2023 in Milan on Friday May 5th
Data is presented by Andreas Fasth, Head of Clinical Development and Medical Affairs who will also participate in the two-day EWMA innovation forum with selected experts and stakeholders.